# Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer

> **NCT00263588** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 242 (actual)

## Conditions studied

- Neoplasms, Breast

## Interventions

- **DRUG:** lapatinib

## Key facts

- **NCT ID:** NCT00263588
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12-02
- **Primary completion:** 2007-09-25
- **Final completion:** 2018-03-15
- **Target enrollment:** 242 (ACTUAL)
- **Last updated:** 2019-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00263588

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00263588, "Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00263588. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*